<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00608946</url>
  </required_header>
  <id_info>
    <org_study_id>UKS-PSY-DEM-01</org_study_id>
    <secondary_id>UKS-PSY-DEM-01</secondary_id>
    <nct_id>NCT00608946</nct_id>
  </id_info>
  <brief_title>Treatment With Copper in Patients With Mild Alzheimer´s Dementia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Goettingen, Section Neurobiology (Head: Prof. Dr. T. Bayer), Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of 8 mg of copper daily regarding cognitive function, content of beta amyloid
      protein in the CSF and volumetric changes in the brain will be examined in a first
      double-blind, placebo-controlled human clinical trial conducted in 70 patients with mild
      Alzheimer´s dementia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of cognitive function, measured by ADAS-cog</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of beta amyloid in the CSF and volumetric changes in the brain</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Alzheimer´s Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>efficacy of the intake of 8 mg of copper daily per os for one year under observation of cognitive status unless unacceptable side effects appear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>copper</intervention_name>
    <description>intake of copper orotate 8 mg per day per os, once daily for one year, vs. placebo under observation of the cognitive status</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female patients

          -  between 50 and 80 years

          -  criteria of mild dementia

          -  probable Alzheimer´s dementia according to NINCDS-ADRDA criteria

          -  given written informed consent

          -  having a relative who can fill out questionnaire; caregiver consent

          -  free of serious and unstable somatic illness

        Exclusion Criteria:

          -  unable to give informed consent

          -  unable to take cholinesterase inhibitors

          -  unapproved medication

          -  moderate to severe Alzheimer´s disease

          -  dementia of other etiology

          -  history of alcohol, drug or medication abuse

          -  other psychiatric disorder, e. g. schizophrenia

          -  known copper and zinc storage disease

          -  known copper and zinc intolerance

          -  vegans

          -  known severe allergies or intolerances

          -  insufficient knowledge of the German language

          -  female patients of childbearing potential, pregnant or nursing patients

          -  participation in a clinical trial within the past 30 days before onset of this study

          -  severe somatic diseases and high mortality rate AST, ALT, GGT, GLDH, AP or bilirubin
             being a two-fold above the normal range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank G Pajonk, M.D., lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Psychiatry and Psychotherapy, The Saarland University Hospital</affiliation>
  </overall_official>
  <link>
    <url>http://www.alzheimer-bayer.de</url>
    <description>Dept. of Neurobiology, University of Goettingen (Head: Prof. Dr. T. Bayer)</description>
  </link>
  <reference>
    <citation>Bayer TA, Schäfer S, Simons A, Kemmling A, Kamer T, Tepest R, Eckert A, Schüssel K, Eikenberg O, Sturchler-Pierrat C, Abramowski D, Staufenbiel M, Multhaup G. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14187-92. Epub 2003 Nov 14.</citation>
    <PMID>14617773</PMID>
  </reference>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>February 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <last_update_submitted>February 5, 2008</last_update_submitted>
  <last_update_submitted_qc>February 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Frank-Gerald Pajonk, M.D., Lecturer</name_title>
    <organization>Dept. of Psychiatry and Psychotherapy, The Saarland University Hospital</organization>
  </responsible_party>
  <keyword>efficacy of treatment with copper in patients with mild Alzheimer´s disease</keyword>
  <keyword>cognitive status over time</keyword>
  <keyword>CSF and volumetric data over time (1 year)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Copper</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

